Related Experiment Videos
Increased thrombin generation in a child with a combined factor IX and protein C deficiency
C Negrier1, M Berruyer, A Durin
1Laboratoire d'Hémobiologie, Institut Pasteur, INSERM U331, Faculté A. Carrel, Lyon, France.
Insights
This study details a one-year-old boy with combined protein C and factor IX deficiencies. Results show unexpected coagulation activation, highlighting the clinical significance of protein C deficiency in hemophilia management.
Area of Science:
- Hematology
- Coagulation Disorders
- Pediatric Medicine
Background:
- A one-year-old boy presented with concurrent severe factor IX deficiency (inherited from mother) and moderate protein C deficiency (inherited from father).
- Factor IX activity and antigen levels were <1%, while protein C activity and antigen were ~27% of normal.
- This dual deficiency presents complex therapeutic and prognostic challenges due to thrombotic risks associated with protein C deficiency and potential thrombogenicity of factor IX concentrates.
Abstract:
We report a quantitative protein C deficiency combined with a factor IX deficiency in a one-year-old boy. The inheritance of the two deficiency states was independent, the factor IX defect coming from the mother and the protein C defect from the father. Both factor IX activity and antigen were below 1%, and protein C activity as well as antigen were close to 27% of normal values. This association raises a real therapeutic and prognostic question. Protein C deficiency is indeed associated with a significant thrombotic risk and some factor IX concentrates seem to carry a potential thrombogenicity, particularly following infusion of repeated doses. We evaluated in this patient the potential activation of the coagulation system by measuring the levels of prothrombin fragment F1 + 2 at the basal state and after a single administration of 20 U/kg of a high purity factor IX concentrate. We found an unexpected basal activation of the hemostatic system before infusion (F1 + 2 = 1.6 nmol/L), which further increased during 8 hours. Despite the clinical predominant expression of the hemophilic trait, our results seem to assess the biologic prevalence of the protein C deficiency. This emphasizes the need for a careful follow-up after infusions of repeated doses of factor IX, as used during a surgical procedure. Furthermore, this raises the question of the prognosis because the risk of thrombotic manifestations associated with a protein C deficiency increases with age. Finally, these results highlight a part of the in vivo activation process of prothrombin in case of failure of the intrinsic pathway of coagulation. The protein C defect seems to be responsible for an upregulation of the prothrombin activation through the extrinsic pathway.